INCYTE
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Delaware, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
1801 Augustine Cut Off, Wilmington, Dela...Phone Number
(302) 498-6700Website
www.incyte.comRevenue
$5.8 BillionStock Symbol
INCYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
1
1
1
About INCYTE
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.Explore more
INCYTE Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is INCYTE your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if INCYTE has recently received funding, and reach out quickly before it becomes old news!
Click to see if INCYTE had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once INCYTE has new funding data
Congratulate Masked Content for being promoted to Masked Content at INCYTE
Earning: See what the market has to say on INCYTE recently announced quarterly report
INCYTE, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if INCYTE is spiking on competitors!
Product Launch: Get notified when INCYTE launches new products
Recommended Actions
Reach out to Masked Content who joined INCYTE as Masked Content
Find 3 more new buyers
Compare Similar Companies to INCYTE
Compare insights from companies similar to INCYTE, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$4.5B
5K - 10K
Public
$846M
1998
JT
Jacqueline TranSenior Executive Administrative Partner To Chief Marketing Officer
Company Profile Activity
Activity Insights
INCYTE is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
INCYTE is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about INCYTE.
INCYTE Tech Stack
A closer look at the technologies used by INCYTE
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Open Position
INCYTE News & Media
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks
In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]Incyte Corporation (INCY) vs. Revolution Medicines (RVMD): Which Biotech Stock Offers the Better KRAS Opportunity?
Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal […]Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
Incyte Corp (INCY) reports a 38% increase in total revenue, raises full-year guidance, and highlights significant advancements in its diverse product pipeline.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INCYTE
Sign Up For FreeTo access detailed company insights
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome... Read More
